Arrowhead Pharmaceuticals’ (ARWR) “Buy” Rating Reaffirmed at Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $115.00 price target on the biotechnology company’s stock. Chardan Capital’s target price would indicate a potential upside of 96.73% from the company’s current price.

A number of other brokerages also recently weighed in on ARWR. B. Riley Financial raised their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Morgan Stanley boosted their price objective on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Leerink Partners boosted their price objective on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th. Piper Sandler reissued an “overweight” rating and set a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 31st. Eleven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock traded up $0.09 during trading on Thursday, reaching $58.46. The company had a trading volume of 903,735 shares, compared to its average volume of 2,286,660. The firm’s 50 day simple moving average is $76.71 and its two-hundred day simple moving average is $75.99. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals has a one year low of $36.57 and a one year high of $95.49. The company has a market capitalization of $8.23 billion, a PE ratio of -25.91 and a beta of 1.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same period in the previous year, the business posted ($1.26) earnings per share. The firm’s revenue was up 171.0% on a year-over-year basis. Sell-side analysts forecast that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current year.

Insider Activity

In other news, Director Michael Perry sold 11,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the sale, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Adeoye Olukotun sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director owned 31,600 shares in the company, valued at approximately $2,747,936. This represents a 5.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of ARWR. Sax Wealth Advisors LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $624,000. GAMMA Investing LLC grew its stake in shares of Arrowhead Pharmaceuticals by 17.1% in the 3rd quarter. GAMMA Investing LLC now owns 4,542 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 663 shares during the period. QRG Capital Management Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 7.1% in the 2nd quarter. QRG Capital Management Inc. now owns 4,810 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 317 shares during the period. Integrated Wealth Concepts LLC grew its stake in shares of Arrowhead Pharmaceuticals by 5.2% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 8,297 shares of the biotechnology company’s stock valued at $676,000 after purchasing an additional 412 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at approximately $20,859,000. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals News Summary

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Positive ARO-MAPT results: Interim Phase 1/2a data showed up to a 73% reduction in tau, a protein associated with Alzheimer’s disease, with reductions described as deep and durable in healthy volunteers. The company said the results provide the first clinical validation of its TRiM platform’s ability to deliver siRNA across the blood-brain barrier and reduce a target gene in the brain. Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data
• Positive Sentiment: Alzheimer’s program strengthens the pipeline: The reported ability to cross the blood-brain barrier could support ARO-MAPT and other programs using Arrowhead’s TRiM CNS delivery platform. Coverage highlighted the potential significance of the early-stage data, although the study remains investigational and was conducted in healthy volunteers. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: Analysts reaffirm bullish views: Chardan Capital reiterated its “buy” rating and set a $115 price target, while HC Wainwright also reaffirmed “buy” with a $120 target. Both targets imply substantial upside from recent trading levels, providing additional support for investor sentiment.
• Neutral Sentiment: Important clinical caveat: The ARO-MAPT findings are interim Phase 1/2a results and primarily demonstrate biomarker reduction and delivery, not yet proof that the therapy improves cognition or slows Alzheimer’s disease. Further clinical testing will be needed to establish efficacy and safety. Arrowhead Discusses ARO-MAPT Interim Results and TRiM CNS Delivery
• Neutral Sentiment: Some coverage noted differing analyst views on healthcare stocks, including Arrowhead, indicating that valuation and execution risks remain despite the favorable ARO-MAPT update.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.